Cubist Systematic Strategies’s Axsome Therapeutics AXSM Stock Holding History

Cubist Systematic Strategies’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$717K	Hold	5,900	–	–	﹤0.01%	2106
2025 Q2	$616K	Hold	5,900	–	–	﹤0.01%	2166
2025 Q1	$688K	Buy	+5,900	New	+$672K	﹤0.01%	2020
2024 Q1	–	Sell	-7,600	Closed	-$605K	–	3706
2023 Q4	$605K	Hold	7,600	–	–	﹤0.01%	2421
2023 Q3	$531K	Hold	7,600	–	–	﹤0.01%	2282
2023 Q2	$546K	Buy	7,600 +1,200	+19%	+$88.5K	﹤0.01%	2338
2023 Q1	$395K	Buy	+6,400	New	+$420K	﹤0.01%	2818

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cubist Systematic Strategies's AXSM Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Axsome Therapeutics (AXSM) stake by 87% in Q3 2025, selling an estimated $15.6M and leaving 21,165 shares worth $2.57M. The position accounts for 0.01% of the portfolio, ranked #1407.

Cubist Systematic Strategies first reported a position in AXSM in Q2 2019 and has held it in 19 quarters since. The position peaked at $20.7M in Q1 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

Cubist Systematic Strategies held 21,165 shares of Axsome Therapeutics worth $2.57M as of Q3 2025.
Cubist Systematic Strategies sold 138,068 Axsome Therapeutics shares in Q3 2025, an estimated $15.6M.
Axsome Therapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1407 holding.
Cubist Systematic Strategies first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 19 quarters since.
Cubist Systematic Strategies's Axsome Therapeutics position peaked at $20.7M in Q1 2025.
355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.